Podcasts about metastatic

Metastatic breast cancer cannot be cured but it can be treated. Treatment focuses on disease management while maintaining the best possible quality of life. The unfortunate reality is that a treatment will only work for so long, then another one is needed. Joining us today are two women living with metastatic breast cancer who are sharing their experiences, living one treatment to the next. They are tireless advocates for research and the breakthroughs that will ensure their next treatment is available, when they need it. They're sharing how they live life to the fullest and manage their day-to-day care. Key Takeaways It's important to find hope while living treatment to treatment Recognize the physical and emotional toll of treatment, even when you look well Advocate for research, clinical trials, and discoveries that lead to better treatments Live in the present, prioritize quality of life, and give yourself grace Chapters 00:00 — Living with metastatic breast cancer 03:25 — The reality of treatment after treatment 07:45 — The emotional weight of uncertainty 13:23 — Why metastatic breast cancer research matters 26:34 — Living in the present and finding hope Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

What happens when your life changes in an instant, and then, just when you think you're beginning to rebuild, you're faced with another life-altering diagnosis? Shannon Michelle knows that experience firsthand. After a devastating motorcycle accident left her in a coma with a traumatic brain injury, Shannon had to relearn how to walk, read, speak and navigate a life she no longer remembered. Then, during her recovery, she was diagnosed with breast cancer. Today, Shannon joins us to talk about her breast cancer experience, the emotional realities of healing, and how an unimaginable series of events changed the way she sees her life. Key Takeaways Stay present, especially when life feels overwhelming Self-care is essential to recovery Accepting a new reality can be empowering Let go of what you cannot control Give yourself permission to be the best version of yourself today Chapters 00:00 — Surviving a devastating accident 04:30 — A breast cancer diagnosis 07:57 — The PATCH framework for healing 16:50 — Accepting a new reality 23:50 — Letting go of control Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Bret Miller was 17 when he first felt a lump behind his nipple. For seven years, providers told him it was calcium buildup or that it would go away on its own. It didn't. At 24, Bret was diagnosed with Stage 1 breast cancer — a disease most people, including many of the doctors he saw along the way, don't associate with men at all.In this episode, Bret joins his oncologist, Dr. Priyanka Sharma of The University of Kansas Cancer Center, to unpack why male breast cancer is so often missed or overlooked by so many health care providers — and why most men have never been told what normal breast tissue looks or feels like for them in the first place. Together, they talk about what needs to change in clinical training and patient conversations, and what self-advocacy looks like when the system isn't built to catch what you're describing. This episode is part of the Komen Health Equity Revolution podcast series, which centers the lived experience of communities too often overlooked in breast cancer awareness and care — including men. 5 Key Takeaways Men need to know the signs and symptoms of breast cancer A persistent change in one breast should be investigated Nipple discharge can be a warning sign of breast cancer Patients should advocate for themselves and seek second opinions Healthcare providers should take concerning breast changes seriously Chapters 03:10 Bret's Seven-Year Journey to a Diagnosis 10:55 Why Male Breast Cancer Gets Missed 15:09 Knowing What Is Normal for Men 17:11 Turning a Diagnosis Into Advocacy 24:39 How Healthcare Providers Can Close the Gap Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Matt Smith, 42, metastatic prostate cancer, Wilmington, NC, with Michael Serzan, Medical Oncologist, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute

Breast cancer treatment has a beginning and an end, but healing is often a much longer journey. Today, we are joined by Katie Wasserman, a remarkable mother of four who shares how trusting her instincts and advocating for herself led to her breast cancer diagnosis. She will talk about navigating treatment decisions, the impact it had on her body, and the physical and emotional healing that continues today into survivorship. From managing the fears that linger after treatment ends to intentionally choosing a life focused on thriving instead of simply surviving, Katie's story is a powerful reminder that no one knows your body better than you do. Key Takeaways Trust your instincts when something feels wrong Self-advocacy can lead to life-saving care Asking for help strengthens recovery Small daily habits support healing and resilience Survivorship is about thriving, not just surviving Chapters 00:00 – Trusting your instincts 05:09 – The power of self-advocacy 07:51 – Recovery, support, and staying active 15:04 – Sharing the journey through Instagram 18:27 – Thriving beyond survivorship Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

When multiple loved ones are diagnosed with breast cancer within a short period of time, it can leave you wondering if, and when, it might become part of your own story. Megan May knew her family history meant that she was at greater risk of developing breast cancer. She prepared as best she could and underwent regular screenings. However, her diagnosis at age 40 still came as a shock because there are some things that no one can fully prepare you for. Megan is here today to share her story - how a series of family diagnoses prompted her to begin early screening, what it was like to hear the words no one wants to hear, and the physical and emotional challenges that followed. We'll talk about how why giving back through fundraising has become such an important part of her mission and how her family supports each other through it all. Key Takeaways Family history can help identify when earlier screenings are needed Early detection can allow cancer to be caught and treated quickly Supporting someone with cancer starts with simply being present Knowing your normal and getting screened can save lives Chapters 00:00 – Megan's family history with breast cancer 02:20 – Starting early screenings 04:04 – Megan's diagnosis and treatment journey 09:39 – Finding strength through movement and survivorship 14:46 – Supporting family and advocating for early detection Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Highlights from the PER® CME activity "From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts William Gradishar, MD, FASCO, FACP; and Kamel Abou Hussein, MD; discuss optimizing first-line treatment selection in metastatic triple-negative breast cancer (TNBC) with emerging antibody-drug conjugates (ADCs) and biomarker-guided strategies.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/from-trials-to-the-clinic-incorporating-new-advances-in-metastatic-tnbcThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In today's episode, we spoke with Marlana M. Orloff, MD. Dr Orloff is the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. In our exclusive interview, Dr Orloff discussed the distinct biology of uveal melanoma and why it has historically resisted systemic treatment. Unlike cutaneous melanoma, which carries a high tumor mutational burden and responds robustly to immune checkpoint inhibitors, uveal melanoma sits at the opposite end of the spectrum with low mutational burden, a predominantly liver-metastatic pattern, and an immune-tolerant microenvironment that renders traditional immunotherapy largely ineffective.She provided context on the treatment landscape for patients with HLA-A*02:01–negative metastatic uveal melanoma prior to the phase 2/3 OptimUM-02 trial (NCT05987332), noting that this population had limited options: liver-directed therapies such as percutaneous hepatic perfusion, off-label immune checkpoint inhibitor combinations, or clinical trial enrollment.Dr Orloff then walked through the design and efficacy findings of the trial, which evaluated the combination of darovasertib, an oral PKC inhibitor, plus crizotinib (Xalkori), a MET inhibitor, vs investigator's choice in treatment-naive, HLA-A*02:01–negative patients. The combination demonstrated a median progression-free survival of 6.9 months vs 3.1 months with investigator's choice, with an objective response rate of 37.1% compared with under 5.8% in the control arm. She highlighted the clinical significance of the complete responses observed while noting that overall survival data from the phase 3 portion of the trial remain pending.The discussion also addressed the growing complexity of treatment sequencing as more options emerge, including tebentafusp-tebn (Kimmtrak) for HLA-A*02:01–positive patients, liver-directed and combination approaches, and the investigational TCR-engineered T-cell therapy anzutresgene autoleucel targeting PRAME. Dr Orloff emphasized that in the absence of head-to-head comparisons, sequencing decisions will increasingly be shaped by patient logistics, toxicity profiles, and access to specialized treatment centers.

For this Managed Care Cast episode, The American Journal of Managed Care® (AJMC®) spoke with Anuraag R. Kansal, PhD, who leads health economics research at GRAIL, about his study, “State Medicaid Budgetary Implications of New Cancers," published in the July 2026 issue; it examined how new cancer diagnoses affected state Medicaid budgets. He conducted the study with Amanda C. Chen, PhD, of the USC Mann School of Pharmacy and Pharmaceutical Sciences, and David C. Grabowski, PhD, of Harvard Medical School. Kansal explained to AJMC that despite Medicaid's younger population, cancer remains the third-largest source of program spending. Most existing research had focused on commercial and Medicare populations rather than Medicaid specifically. Consequently, using de-identified CMS claims data, he and his team identified new cancer diagnoses, defined as no prior cancer evidence in the preceding 6 months, and compared spending, hospitalizations, and emergency department use between metastatic and non-metastatic cases. Kansal highlighted the core finding, which was that metastatic diagnoses were associated with significantly higher spending than non-metastatic diagnoses across most cancer types. Notably, health care utilization patterns were consistent between fee-for-service and capitated Medicaid states, suggesting that cost drivers stemmed from the disease itself, particularly the shift to systemic therapies once cancer spread, rather than from program administration models. Kansal pointed to the 4 cancer screenings recommended by the US Preventive Services Task Force, namely lung, breast, colorectal, and cervical, as opportunities to reduce late-stage diagnoses and their associated costs while noting that cancers without established screening protocols presented a distinct policy challenge. On balancing innovative treatment access with cost sustainability, he emphasized that Medicaid's state-by-state administration means that no single policy solution applied universally. Still, Kansal emphasized that earlier detection could offer states greater financial flexibility to support innovative therapies for patients with true clinical need. “Intervening earlier is one of the opportunities we might have to really make a difference,” he concluded.

Disability and breast cancer intersect in more than one direction. Some people develop long-term effects like lymphedema, neuropathy or cognitive changes because of treatment — effects recognized as disabilities under the Americans with Disabilities Act. Others are already living with a disability, of any kind, when a breast cancer diagnosis enters the picture. This July, in recognition of Disability Pride Month, Krista Park Berry, Director of Susan G. Komen's Breast Care Helpline, returns to Real Pink to talk about how the Helpline supports people through their breast health experience no matter when their disability started, and what that support looks like for women of color in particular. Key takeaways No two disability experiences are the same Disability can exist before or develop after breast cancer treatment The Komen Breast Care Helpline provides personalized support and resources Accessible, whole-person care improves quality of life and health outcomes Chapters 00:00 – Understanding disability and breast cancer 02:08 – Treatment-related disabilities and ADA protections 06:26 – Supporting people living with metastatic breast cancer 08:11 – Navigating breast cancer with a pre-existing disability 12:11 – Health equity, women of color, and closing care gaps 13:36 – Why asking for help can change everything

Artificial Intelligence is buzzy. There's a lot about it in the news and a lot we think we understand about how to use it and a lot we may not fully understand. But the promise it holds is tremendous, and today we're going to learn a little more about how it could benefit breast cancer research and patient care in the near future. Drs. Charles Perou at UNC Chapel Hill and Erika Crosby at Duke University are two very accomplished breast cancer researchers who are joining us today to share their perspectives on using AI now and in the future. Key takeaways AI is improving breast cancer screening and diagnosis. Researchers are using AI to save time on coding, writing, and data analysis. AI can help match patients to clinical trials more effectively. Human expertise is still needed to verify AI-generated results. AI has the potential to accelerate research and improve patient care. Chapters 00:00 — Introduction to AI in Breast Cancer Research 02:53 — Ethical Considerations and Responsible AI Use 04:33 — Current Clinical Applications of AI 08:12 — How Researchers Are Using AI in the Lab 11:17 — AI Limitations, Mistakes, and Critical Thinking 17:23 — The Future of AI-Assisted Cancer Research Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

We know that clinical trials are a critical lifeline, offering new ways to prevent, detect, diagnose and treat breast cancer. Today, patient advocates are transforming clinical trials by bringing the real-world experiences of patients directly to researchers. By acting as a bridge between science and the community, patient advocates boost enrollment in clinical trials, and help build a lasting trust Today we are speaking with Dr. Lior Braunstein, a radiation oncologist and researcher at Memorial Sloan Kettering Cancer Center, and Dr. Ellen Landsberger, a retired OB-GYN and patient advocate, also at Memorial Sloan Kettering Cancer Center. Together they are working on the ARCHER clinical trial, a study that is investigating a new treatment strategy for HER2-positive metastatic breast cancer. We'll talk about what they are hoping to accomplish through the ARCHER trial, what their collaborative process looks like and how patient advocates in clinical trials can help improve patient outcomes. Key Takeaways: Patient advocates help design better clinical trials The ARCHER trial aims to improve treatment outcomes Patient voices shape research from the very beginning Clinical trials study both treatment and quality of life Better access helps more patients join clinical trials Chapters 00:00:00 – Why patient advocates belong at the clinical trial design table 00:04:44 – From breast cancer survivor to patient advocate 00:07:46 – How advocates shape research and address patient concerns 00:12:08 – Inside the ARCHER trial and its goal to improve metastatic breast cancer treatment 00:19:03 – Measuring quality of life and improving access to clinical trials 00:26:28 – How patients can become advocates and influence future research

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FJQ865. CME credit will be available until June 24, 2027.New Kids on the Block in Pretreated Metastatic EGFRm NSCLC: Emerging Strategies to Overcome Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

At just 32 years old, Keisha Kinison was working in women's health when she suddenly found herself as the patient. In this episode, we'll talk about what it was like to discover her diagnosis before a physician had the chance to call, why she made the difficult decision to change doctors during treatment, how her experience transformed her and the incredible support that helped carry her through. Woven throughout every chapter of her story is one powerful message: trust yourself, advocate for yourself, and never be afraid to seek the care you deserve. Key takeaways: Breast cancer can happen at a young age Self-advocacy is essential A strong support system makes a difference Treatment can involve unexpected setbacks Know your body and don't ignore changes Chapters 00:00 Keisha's breast cancer diagnosis at age 32 01:52 Testing, imaging, and receiving the diagnosis 05:12 Triple-negative breast cancer and treatment challenges 09:15 Advocating for herself and changing oncologists 12:11 The support that carried her through treatment 15:33 How cancer changed her career and advice for others Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program at Winship Cancer Institute at Emory University.

There is a lot of conversation right now about funding for cancer research and possible cuts to research projects that will improve our understanding and treatment of breast cancer. I'm pleased to be joined today by two researchers who are sharing their perspectives on the inextricable link between grant funding and sustained research. Dr. Benjamin Schrank is an Assistant Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and Dr. Donald McDonnell is the Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology at Duke University School of Medicine. Dr. McDonnell is a well-established researcher whose work focuses on developing new drugs to treat metastatic breast cancer. Dr. Schrank is early in his research career and focused on harnessing the body's immune system to improve response to treatments for metastatic breast cancer. Both recently received research grants from Susan G. Komen to support their innovative work that will help improve breast cancer care and patient outcomes. Key Takeaways: Breakthrough cancer treatments can take decades to develop Fundamental research is the foundation of future therapies Early-stage funding is critical for innovation Research funding directly impacts patients Chapters 00:00 Introduction 01:40 Meet the researchers and their current projects 03:45 Why medical breakthroughs take decades to achieve 11:15 The critical role of grant funding in scientific research 20:20 Supporting the next generation of cancer researchers Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics: Introduction: Where We Are; Where We're Heading (0:00) First-Line Treatment of BRCA Wild-Type Disease (9:14) First-Line Treatment of BRCA-Mutant Disease (38:48) Novel Approaches (47:49) CME information and select publications

Welcome to the Komen Health Equity Revolution series on Real Pink — where patients, advocates, researchers and community partners come together to talk honestly about what's standing in the way of breast health equity, and what we're doing to change it. June is Pride Month — a time to celebrate identity, community and the courage it takes to live authentically. Today's conversation sits right at the heart of that. Because advocating for yourself, knowing your body and refusing to be dismissed, that's not just a health message. That's a love letter to who you are. Our guest today is Shelby Smith. She was 30 years old when she noticed something felt off. No family history of breast cancer. Young, healthy, going about her life as a wife and mom to a 7-year-old daughter. But she trusted herself — and that decision changed everything. Shelby faced a 12-centimeter tumor, a bilateral mastectomy, 16 rounds of chemo and 15 rounds of radiation. She did her own research, built her own notebook, asked her own questions — and came out the other side with a message she wants every young woman to hear: Know your normal. And when something doesn't feel right, advocate for yourself. Key Takeaways: Trust your instincts when something feels off Self-advocacy can change outcomes Being informed helps patients navigate treatment Cancer can affect more than physical health Including loved ones in the journey matters Chapters 00:00 Introduction: Shelby's Breast Cancer Story 02:07 Discovering a Lump and Seeking Answers 04:37 Diagnosis, Testing, and Receiving the News 10:07 Research, Self-Advocacy, and Navigating Treatment 17:33 Identity, Family, and Talking to Her Daughter 24:46 Life After Treatment and Advice for Young Women Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

A breast cancer diagnosis may feel like it changes your entire life in an instant, but it doesn't get to define who you are or make all your choices for you. On today's episode of Real Pink, we're joined by Amanda Sangemino, a remarkable young woman whose diagnosis came at an age when cancer was likely the last thing on her mind. What began with a concern that was initially dismissed ultimately led her to trust her instincts, advocate for herself, and make a series of personal decisions about her treatment and future. Throughout the process, she was determined not to let fear and cancer make every decision for her. Today, she'll talk about the choices that she made about fertility, surgical options and maintaining an active lifestyle and why trusting yourself can be one of the most powerful tools you have. Key Takeaways: Mindset can play a powerful role during treatment Trust your instincts and advocate for yourself Maintaining normalcy can be empowering Don't let cancer make every decision for you A strong support system makes a difference Chapters: 00:00 – Amanda's Breast Cancer Story Begins 01:28 – Finding a Lump and Receiving a Misdiagnosis 04:22 – Seeking a Second Opinion and Getting Answers 07:00 – Why Self-Advocacy Matters for Young Women 10:00 – Fertility, Menopause, and Treatment Decisions 14:43 – Choosing Surgery, Staying Active, and Building Support 23:09 – Amanda's Final Advice Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study:https://www.annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer:https://www.nejm.org/doi/full/10.1056/NEJMoa1903307 ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patientshttps://www.sciencedirect.com/science/article/pii/S0302283825048766 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer:https://www.nejm.org/doi/abs/10.1056/NEJMoa2502929 PROMISE Registry:https://www.prostatecancerpromise.org/ Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00683-X/abstract --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases. The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics. In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.   Key Points: In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone. Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off. Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity. Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression. Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology! #EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

Today on National Cancer Survivor's Day, we're joined by a remarkable performer whose strength, vulnerability, and resilience have inspired millions around the world. She has taken the stage as a backup vocalist for numerous top artists and most recently dazzled the crowds on the biggest tour in music history with global superstar Taylor Swift. However, audiences were moved even more deeply when she chose to publicly share something far more personal – her breast cancer journey. After Jeslyn Gorman's diagnosis become known through The Eras Tour docuseries, fans witnessed the emotional reality of navigating cancer while stepping away from a career and community she loves so deeply. From continuing to tour in the early days of diagnosis, to facing treatment side effects and returning to the stage immediately following treatment, her story is one of courage, grace and resilience. Today, Jeslyn opens up about the support she received, what survivorship looks like now and most importantly, shares an empowering message for young women about listening to their bodies, advocating for their health, and never underestimating the importance of early detection. Key Takeaways: Early detection can save lives. You can experience joy and fear at the same time. A strong support system makes a major difference. Recovery is gradual and requires patience. Cancer changes your life, but it doesn't define it. Chapters 00:00 – Jeslyn's Breast Cancer Diagnosis 05:24 – Continuing to Perform After Diagnosis 07:38 – Going Public With Her Cancer Story 13:22 – Breast Health and Self-Advocacy 18:07 – Support From Family, Friends, and the Tour Community 22:17 – Staying Positive During Treatment 25:17 – Chemotherapy and Physical Recovery 31:49 – Hair Loss and Identity Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship. 37:29 – Life After Treatment and Survivorship

Has America abandoned the values that once shaped Western civilization? In this episode of 1819 News: The Podcast, host Bryan Dawson examines Pride Month, the rise of what he calls "Christless Conservatism," and the cultural forces he believes have transformed America over the last several decades. Bryan discusses the sexual revolution, the role of modern conservatism, the decline of traditional family values, and why he believes the Christian family remains the foundation of a healthy society. He also explains why many conservatives failed to resist cultural change and what Christians can do to reclaim their influence in the public square. Topics include: • Pride Month and modern cultural politics • The rise of Christless Conservatism • Faith, family, and Western civilization • The sexual revolution and its consequences • Christian responsibility in the culture war • Building strong families in a changing America Subscribe to 1819 News for more conversations on faith, culture, politics, and the issues shaping Alabama and the nation.

Has America abandoned the values that once shaped Western civilization? In this episode of 1819 News: The Podcast, host Bryan Dawson examines Pride Month, the rise of what he calls "Christless Conservatism," and the cultural forces he believes have transformed America over the last several decades. Bryan discusses the sexual revolution, the role of modern conservatism, the decline of traditional family values, and why he believes the Christian family remains the foundation of a healthy society. He also explains why many conservatives failed to resist cultural change and what Christians can do to reclaim their influence in the public square. Topics include: • Pride Month and modern cultural politics • The rise of Christless Conservatism • Faith, family, and Western civilization • The sexual revolution and its consequences • Christian responsibility in the culture war • Building strong families in a changing America Subscribe to 1819 News for more conversations on faith, culture, politics, and the issues shaping Alabama and the nation.

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Arpita Desai discusses metastatic hormone sensitive prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41560]

This episode originally aired in November 2023. When someone has metastatic breast cancer, it is scary for them - and for you! What can you do to really help? What should you say? Is it better to just listen? Today's guest received a de novo metastatic diagnosis in January 2021 and then elected to retire early from a 30-year technology sales career in order to slow life down and to focus on family, friends and thriving with MBC. Carlee Dixon's surprise diagnosis also inspired her to learn as much as possible about breast cancer and take every opportunity to educate friends and acquaintances about breast cancer prevention and the day to day reality. Today, Carlee is here to shed some light on how to best support those who are living with metastatic breast cancer.

It's Women's Health Month — which means a lot of awareness messaging and a lot of conversation about why women's health matters. But today, we're going a level deeper. Because awareness doesn't save lives. Action does. Infrastructure does. Investment does. And honest conversations about why the system isn't working equally for everyone — those matter too. My guest today is Jenica Patterson — a neuroscientist turned health systems architect who is doing the hard work of figuring out why women's health is so chronically underinvested and what it will take to fix it. She leads the Women's Health Network at the Milken Institute, one of the most powerful cross-sector coalitions in this space. Before that, she built a $113 million federal program at ARPA-H (the Advanced Research Project Agency for Health) specifically designed to fast track innovation in women's health. Komen is focused on breast health access — and the sobering reality that where you live and what you look like still determine whether you get a timely mammogram, an accurate diagnosis or the best possible care. Jenica has the research, the relationships and the conviction to tell us exactly why that is — and what's possible. Key Takeaways: Women's health inequities are systemic, not individual. Nearly 30% of U.S. counties do not have a mammography machine. Women's health has historically been underrepresented in research and clinical development. Innovation alone is not enough without integration. Momentum in women's health is growing. Chapters 00:00 Jenica Patterson's journey from neuroscience to women's health systems leadership 05:45 Why women's health is at a major inflection point 08:40 The shocking mammography access gaps across the United States 14:02 Why solving women's health requires system-wide integration 20:03 Where momentum and hope are growing in women's health equity Learn more at realpink.komen.org and komen.org breastcancer #survivorship #womenshealth #cancersupport #realpink Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Menopause – it may be the most unwanted time in a woman's life. It arrives with a vengeance, forcing all kinds of emotional, hormonal and bodily changes onto women as they approach their 50s. But for women going through breast cancer treatment, it can arrive even earlier and be even more unwanted. The good news is no one has to suffer in silence. Today's guests are Dr. Makeba Williams, the incoming president of The Menopause Society, and Claudia McConnell, a breast cancer survivor who was forced into menopause during breast cancer treatment at age 37. Key takeaways Breast cancer treatment can trigger sudden and emotionally overwhelming early menopause Menopause symptoms after cancer treatment are real, serious, and treatable. Mental health support is a critical part of breast cancer survivorship care. Open conversations help reduce stigma and empower women to seek support. Chapters 00:00 Introduction to breast cancer and menopause realities 04:29 Claudia's breast cancer diagnosis and sudden menopause at 37 15:42 Why survivors shouldn't suffer through menopause symptoms alone 19:20 New menopause treatments and advances for breast cancer survivors 21:07 Sleep disruption, insomnia, and menopause management strategies 24:07 Estrogen creams, vaginal health, and treatment decision-making 30:19 BRCA2, talking to children about cancer risk, and family support 39:05 Final advice for women navigating menopause after breast cancer Learn more at realpink.komen.org and komen.org breastcancer #menopause #survivorship #womenshealth #cancersupport #realpink Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors and key findings from the Phase III PROpel study (11:03) Key findings from the Phase III MAGNITUDE and TALAPRO-2 studies (15:10) Summary of efficacy data with PARP inhibitors; toxicities (20:01) Key findings and conclusions from the Phase III AMPLITUDE study; future directions with PARP inhibitors (23:33) CME information and select publications

Featuring an interview with Dr Wassim Abida, including the following topics: Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00) Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37) Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33) Key considerations surrounding toxicities associated with PARP inhibitors (15:25) Potential role of saruparib; evolving nomenclature in prostate cancer (22:36) Approach to newly diagnosed metastatic prostate cancer (26:16) Clinical relevance of PSMA-targeted PET imaging results (29:49) Case: A man in his mid 70s with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration receives olaparib/abiraterone/prednisone upon relapse (32:15) Combining PARP inhibitors with other DNA repair inhibitors; insights on the PSMAddition trial (37:14) Case: A man in his mid 60s with metastatic prostate adenocarcinoma and a BRCA germline mutation receives niraparib/abiraterone/prednisone (43:17) Case: A man in his early 60s with mCRPC and CDK12 mutations receives talazoparib/enzalutamide (45:54) CME information and select publications

While menopause is often associated with aging, many women facing breast cancer experience it suddenly and much earlier than expected—bringing a wave of physical and emotional changes. From managing intense symptoms to confronting fears about future family-building, the journey can feel overwhelming. On today's episode, we are joined by Melody Johnson, a nurse practitioner who specializes in caring for women navigating these exact challenges. She will help us understand how treatment-induced menopause differs from natural menopause and the strategies available to cope with side effects while already carrying so much. We'll also take a closer look at fertility—an especially emotional and complex issue for younger women diagnosed before they've had the chance to start or grow their families. Whether you're newly diagnosed, supporting someone who is, or simply want to better understand this critical aspect of women's health, this conversation is here to inform, support, and remind you: you are not alone on this journey. What You'll Learn: • The difference between treatment-induced and age-related menopause • Common symptoms and why they can feel more severe during cancer treatment • How to manage menopause side effects alongside a breast cancer diagnosis • Fertility preservation options, including egg freezing and when to consider them • Why self-advocacy is critical when discussing fertility with your care team Chapters: 00:00 Introduction to treatment-induced menopause 01:29 Melody Johnson's background in oncofertility 02:45 What to expect from menopause symptoms 05:05 Key differences between induced and natural menopause 06:24 Managing symptoms during treatment 08:29 Fertility concerns for younger women 10:25 Is treatment-induced menopause permanent? 11:53 Questions to ask your doctor 13:24 Why these conversations matter 14:48 Final advice for women navigating fertility after diagnosis Learn more at komen.org and realpink.komen.org BreastCancer #Fertility #Menopause #WomensHealth #Oncofertility #CancerSupport #ReproductiveHealth #RealPink Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including: Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib. The role of CNS involvement in treatment decisions and the importance of patient-centered care. Strategies for managing disease progression and the significance of re-biopsy. Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib. The latest developments in treating rare mutations like NTRK, MET, RET, and HER2. With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes. Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below! #LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

Today's conversation is one that so many mothers will feel deep in their bones because it talks about what happens when life asks you to be the one who needs care. Our guest today has lived that shift in a profound way. In the midst of raising her young children, navigating the everyday chaos and fiercely advocating for her youngest daughter, Nylah, who was born with congenital heart disease, Nisha Jaime was suddenly diagnosed with breast cancer. There is an emotional whiplash to being the strong one for your child and then suddenly needing that same strength for yourself. Nisha will talk to us about what that was like and how she balanced it all with the help of her village. We'll talk about the ongoing realities of survivorship, including things like scanxiety and continued care and how her children are involved in her journey. Most importantly, we'll hear how she has turned her experience into support for other mothers walking a similar path and why that mission matters so deeply to her.

What does it take to turn the most terrifying moment of your life into a movement? For Yvonne McLean Florence, it started with discovering a lump she acted on right away. Yvonne is a HER2-positive breast cancer survivor, ordained minister, Worship in Pink Ambassador, former founder of Sisters R Us Circle of Survivors (SRUCOS) and is currently the reigning Ms. Pennsylvania Senior America 2025. But before all of that, she was a wife, a mother, a grandmother — and suddenly, a patient. In this powerful episode of Real Pink, Yvonne joins host Adam Walker to talk about what it felt like to receive a life-changing diagnosis, how her faith in God, family and friends carried her through chemotherapy and Herceptin infusions, and why she didn't stop when treatment ended. She'll share how she's bringing the conversation about breast health into churches across Philadelphia through Worship in Pink, what it means to build a Cancer Survivorship Resource Nook inside a congregation, and why she would like every survivor to discover how they can also reach back. This episode is part of our Health Equity Revolution series, which lifts up the voices, stories and solutions of the communities most impacted by breast cancer disparities.